Eric Delabesse

List of Publications by Year in Descending Order

149 papers	14,004 citations	41 h-index	118 g-index
157 ext. papers	15,658 ext. citations	5.7 avg, IF	5 L-index

#	Paper	IF	Citations
149	Genomic landscape of hyperleukocytic acute myeloid leukemia.. *Blood Cancer Journal*, **2022**, 12, 4	7	1
148	Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes. *Blood Cancer Journal*, **2021**, 11, 180	7	
147	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. *Leukemia*, **2021**,	10.7	7
146	GATA2 deficiency phenotype associated with tandem duplication GATA2 and over-expression of GATA2-AS1. *Blood Advances*, **2021**,	7.8	1
145	Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial. *European Journal of Haematology*, **2021**, 107, 111-121	3.8	2
144	Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia. *Blood*, **2021**, 137, 1424-1428	2.2	11
143	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. *Leukemia*, **2021**, 35, 1291-1300	10.7	1
142	CD34CD38CD123 Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. *Cancers*, **2020**, 12,	6.6	4
141	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. *Blood*, **2020**, 136, 698-714	2.2	16
140	More than ten percent of relapses occur after five years in AML patients with mutation. *Leukemia and Lymphoma*, **2020**, 61, 1226-1229	1.9	3
139	Outcome of Relapsed or Refractory -Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study. *Cancers*, **2020**, 12,	6.6	4
138	Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. *PLoS ONE*, **2020**, 15, e0238795	3.7	3
137	Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. *Blood Advances*, **2020**, 4, 3840-3849	7.8	4
136	Real-World Outcomes of Patients with Refractory or Relapsed -ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. *Cancers*, **2020**, 12,	6.6	3
135	Outcome of relapsed/refractory AML patients with IDH1 mutations in real life before the era of IDH1 inhibitors. *Leukemia and Lymphoma*, **2020**, 61, 473-476	1.9	1
134	Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. *Clinical Cancer Research*, **2020**, 26, 3307-3318	12.9	5
133	Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience. *Cancer Medicine*, **2019**, 8, 3846-3854	4.8	9

132	Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. *Leukemia Research*, **2019**, 81, 82-87	2.7	8
131	B-ALL With t(5;14)(q31;q32); Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar -Rearranged B-ALL. *Frontiers in Oncology*, **2019**, 9, 1374	5.3	12
130	The impact of chronic myeloid leukemia on employment: the French prospective study. *Annals of Hematology*, **2019**, 98, 615-623	3	3
129	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. *European Journal of Haematology*, **2019**, 102, 131-142	3.8	30
128	P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. *Blood*, **2019**, 133, 280-284	2.2	24
127	A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia. *Leukemia and Lymphoma*, **2018**, 59, 2489-2492	1.9	3
126	Dexamethasone in hyperleukocytic acute myeloid leukemia. *Haematologica*, **2018**, 103, 988-998	6.6	31
125	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. *Haematologica*, **2018**, 103, 1278-1287	6.6	74
124	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. *Leukemia*, **2018**, 32, 2066-2069	10.7	3
123	Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms. *Blood*, **2018**, 132, 2806-2806	2.2	1
122	Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine. *Blood*, **2018**, 132, 1467-1467	2.2	
121	More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission. *Blood*, **2018**, 132, 2802-2802	2.2	
120	TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine. *Blood*, **2018**, 132, 2745-2745	2.2	
119	and isoforms are both efficient to drive B cell differentiation. *Oncotarget*, **2018**, 9, 32841-32854	3.3	3
118	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. *Journal of Clinical Oncology*, **2018**, 36, 3203-3210	2.2	18
117	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. *Journal of Clinical Oncology*, **2018**, 36, 2514-2523	2.2	57
116	PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 10357-10362	11.5	10
115	Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis. *Leukemia Research*, **2018**, 75, 7-10	2.7	1

114	Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. *Leukemia Research*, **2017**, 61, 62-67	2.7	20
113	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. *Blood*, **2017**, 130, 1832-1844	2.2	44
112	Improved outcome for AML patients over the years 2000-2014. *Blood Cancer Journal*, **2017**, 7, 635	7	39
111	Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. *Haematologica*, **2017**, 102, 1718-1726	6.6	24
110	Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. *Hematological Oncology*, **2017**, 35, 664-670	1.3	24
109	Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia. *Blood Advances*, **2017**, 1, 1760-1772	7.8	30
108	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. *Blood*, **2016**, 127, 882-92	2.2	81
107	CHK1 as a therapeutic target to bypass chemoresistance in AML. *Science Signaling*, **2016**, 9, ra90	8.8	49
106	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. *Journal of Experimental Medicine*, **2016**, 213, 483-97	16.6	54
105	Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice. *Blood*, **2016**, 128, 1718-1718	2.2	1
104	Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia. *Blood*, **2016**, 128, 2892-2892	2.2	1
103	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. *Blood*, **2016**, 128, 762-762	2.2	9
102	Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. *Oncotarget*, **2016**, 7, 73769-73780	3.3	25
101	Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases. *Blood*, **2016**, 128, 2861-2861	2.2	
100	Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia. *Blood*, **2016**, 128, 1636-1636	2.2	
99	Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy. *American Journal of Hematology*, **2016**, 91, 193-8	7.1	18
98	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. *Haematologica*, **2015**, 100, 780-5	6.6	34
97	A novel method for room temperature distribution and conservation of RNA and DNA reference materials for guaranteeing performance of molecular diagnostics in onco-hematology: A GBMHM study. *Clinical Biochemistry*, **2015**, 48, 982-7	3.5	4

96	Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. *Molecular Cancer Therapeutics*, **2015**, 14, 2364-73	6.1	36
95	Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. *American Journal of Hematology*, **2015**, 90, E29-30	7.1	8
94	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. *Blood*, **2015**, 125, 13-21	2.2	129
93	The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations. *Blood*, **2015**, 126, 2542-2542	2.2	3
92	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. *Oncotarget*, **2015**, 6, 8388-96	3.3	52
91	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. *Oncotarget*, **2015**, 6, 38061-78	3.3	16
90	Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML. *Blood*, **2015**, 126, 90-90	2.2	
89	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. *Blood*, **2014**, 123, 3739-49	2.2	225
88	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. *Haematologica*, **2014**, 99, e185-7	6.6	23
87	GATA2, a new oncogene of sporadic and familial acute myeloid leukemias. *Hematologie*, **2014**, 20, 153-160		
86	Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network. *American Journal of Hematology*, **2014**, 89, E244-52	7.1	37
85	Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations. *European Journal of Haematology*, **2014**, 93, 533-6	3.8	11
84	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. *Blood*, **2013**, 121, 2213-23	2.2	248
83	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. *Blood*, **2013**, 121, 822-9	2.2	160
82	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. *Blood*, **2013**, 121, 2618-26	2.2	74
81	Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. *Haematologica*, **2013**, 98, 1414-20	6.6	37
80	The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. *Haematologica*, **2013**, 98, 1711-7	6.6	33
79	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. *Haematologica*, **2013**, 98, 1748-52	6.6	40

78	Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia. *Blood*, **2013**, 122, 1651-1651	2.2	2
77	Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias. *Blood*, **2013**, 122, 2681-2681	2.2	1
76	T315I-Mutated BCR-ABL Induces a Distinct and Specific Molecular Signature With High Expression Of Zinc Finger (ZNF) Transcription Factors. *Blood*, **2013**, 122, 4899-4899	2.2	
75	Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study. *British Journal of Haematology*, **2012**, 159, 599-602	4.5	16
74	PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients. *Leukemia Research*, **2012**, 36, 1365-9	2.7	26
73	TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. *PLoS ONE*, **2012**, 7, e31605	3.7	66
72	Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.. *Blood*, **2012**, 120, 2879-2879	2.2	
71	A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). *Nature Genetics*, **2011**, 43, 673-8	36.3	218
70	Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. *Blood*, **2011**, 117, 5719-22	2.2	35
69	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. *Haematologica*, **2011**, 96, 1792-8	6.6	125
68	TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. *Haematologica* , **2011**, 96, 1059-63	6.6	26
67	Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rβ-deficient mice. *Journal of Clinical Investigation*, **2011**, 121, 384-95	15.9	277
66	International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. *Blood*, **2011**, 118, 2535-2535	2.2	3
65	Efficacy of Frontline 5-Azacytidine in Older AML Patient Unfit for Chemotherapy. *Blood*, **2011**, 118, 2614-2614	2.2	4
64	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. *Oncotarget*, **2011**, 2, 850-61	3.3	26
63	What Is New? An Update of the MLL Recombinome Including the Three Novel Partner Genes ABI2, PDS5A, and TOP3A. *Blood*, **2011**, 118, 1351-1351	2.2	
62	Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. *Blood*, **2011**, 118, 410-410	2.2	
61	Uterine chloroma, aortic thrombus and CALM/AF10 acute myeloid leukemia. *Leukemia Research*, **2010**, 34, e88-90	2.7	2

60	Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. *PLoS ONE*, **2010**, 5, e8893	3.7	25
59	Epidermal growth factor receptor/beta-catenin/T-cell factor 4/matrix metalloproteinase 1: a new pathway for regulating keratinocyte invasiveness after UVA irradiation. *Cancer Research*, **2009**, 69, 3291-9	10.1	22
58	Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. *Journal of Clinical Oncology*, **2009**, 27, 911-8	2.2	411
57	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). *Blood*, **2009**, 114, 3285-91	2.2	231
56	Long-Term Results of the Imatinib GRAAPH-2003 Study in Newly-Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia... *Blood*, **2009**, 114, 3080-3080	2.2	6
55	Primary cutaneous Epstein-Barr virus-related lymphoproliferative disorders in 4 immunosuppressed children. *Journal of the American Academy of Dermatology*, **2008**, 58, 74-80	4.5	21
54	Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. *Journal of Clinical Investigation*, **2008**, 118, 3132-42	15.9	1269
53	Transcriptional activation of the cardiac homeobox gene CSX1/NKX2-5 in a B-cell chronic lymphoproliferative disorder. *Haematologica*, **2008**, 93, 1081-5	6.6	7
52	Primary leptomeningeal ALK+ lymphoma in a 13-year-old child. *Journal of Pediatric Hematology/Oncology*, **2008**, 30, 963-7	1.2	17
51	Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele. *Leukemia*, **2007**, 21, 1232-8	10.7	37
50	The CALM-AF10 fusion is a rare event in acute megakaryoblastic leukemia. *Leukemia*, **2007**, 21, 2568-9	10.7	1
49	A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. *Cancer Genetics and Cytogenetics*, **2007**, 173, 17-22		9
48	Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. *Blood*, **2007**, 109, 1408-13	2.2	260
47	Detection of the MPL W515L mutation in bone marrow core biopsy specimens with essential thrombocythemia using the TaqMan assay. *Human Pathology*, **2007**, 38, 1581-2	3.7	2
46	Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. *Blood*, **2007**, 109, 2202-4	2.2	103
45	Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. *Journal of Clinical Investigation*, **2007**, 117, 2225-32	15.9	197
44	PAX5 Mutations Occur Frequently in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Is Significantly Associated with BCR-ABL1 Fusion Gene.. *Blood*, **2007**, 110, 2806-2806	2.2	1
43	Prognostic Significance of CD20 Expression in Adult B-Cell Precursor Acute Lymphoblastic Leukemia.. *Blood*, **2007**, 110, 2829-2829	2.2	2

42	Novel Spliced MLL Fusions Have Been Identified Involving the MLL Partner Genes ELL, EPS15, MLLT3, and SEPT5.. *Blood*, **2007**, 110, 978-978	2.2	
41	Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia. *Cancer Genetics and Cytogenetics*, **2006**, 169, 174-5		5
40	Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. *Cancer Cell*, **2006**, 10, 363-74	24.3	114
39	Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9. *Genes Chromosomes and Cancer*, **2006**, 45, 575-82	5	4
38	Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17). *Blood*, **2006**, 108, 3484-93	2.2	30
37	Application [illegible]matologie maligne des techniques de biologie mol[illegible]ulaire. *EMC H[illegible] matologie*, **2006**, 1, 1-14		
36	The MLL recombinome of acute leukemias. *Leukemia*, **2006**, 20, 777-84	10.7	175
35	Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. *Leukemia*, **2006**, 20, 793-9	10.7	17
34	HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocation. *Leukemia*, **2006**, 20, 1184-7	10.7	25
33	Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. *Leukemia*, **2006**, 20, 1526-32	10.7	89
32	Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. *Leukemia*, **2006**, 20, 2178-81	10.7	7
31	DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. *Leukemia*, **2005**, 19, 1338-44	10.7	40
30	CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. *Leukemia*, **2005**, 19, 1948-57	10.7	100
29	IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner. *Leukemia*, **2005**, 19, 2337-8	10.7	14
28	Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells. *International Journal of Cancer*, **2005**, 115, 511-8	7.5	25
27	AF4p12, a human homologue to the furry gene of Drosophila, as a novel MLL fusion partner. *Cancer Research*, **2005**, 65, 6521-5	10.1	15
26	Transcriptional regulation of the SCL locus: identification of an enhancer that targets the primitive erythroid lineage in vivo. *Molecular and Cellular Biology*, **2005**, 25, 5215-25	4.8	53
25	Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. *British Journal of Haematology*, **2004**, 127, 509-18	4.5	30

24	Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. *Blood*, **2004**, 104, 4173-80	2.2	85
23	Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.. *Blood*, **2004**, 104, 2741-2741	2.2	6
22	Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. *Blood*, **2003**, 101, 2693-703	2.2	128
21	CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. *Blood*, **2003**, 102, 1000-6	2.2	127
20	Absence of SCL mutations in myeloid malignancies. *British Journal of Haematology*, **2003**, 120, 482-3	4.5	
19	Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'Real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. *Leukemia*, **2003**, 17, 2474-86	10.7	717
18	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. *Leukemia*, **2003**, 17, 2257-317	10.7	2404
17	LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science*, **2003**, 302, 415-9	33.3	2822
16	FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. *Blood*, **2003**, 102, 2198-204	2.2	85
15	Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL?. *Leukemia*, **2002**, 16, 2134-41	10.7	42
14	Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. *EMBO Journal*, **2002**, 21, 3039-50	13	184
13	Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. *Leukemia*, **2002**, 16, 587-93	10.7	132
12	Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. *Blood*, **2002**, 99, 4547-53	2.2	64
11	The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. *Blood*, **2000**, 96, 2254-2261	2.2	49
10	Association of a duodenal follicular lymphoma and hereditary nonpolyposis colorectal cancer. *Modern Pathology*, **2000**, 13, 586-90	9.8	16
9	Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. *Lancet, The*, **2000**, 356, 203-8	40	576
8	Virological and molecular characterisation of a new B lymphoid cell line, established from an AIDS patient with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV viruses. *Leukemia and Lymphoma*, **2000**, 38, 401-9	1.9	25
7	Is Complicated Celiac Disease or Refractory Sprue an Intestinal Intra-Epithelial Cryptic T-Cell Lymphoma?. *Blood*, **1999**, 93, 3154-3155	2.2	17

6	Deregulated expression of the TAL1 gene by t(1;5)(p32;31) in patient with T-cell acute lymphoblastic leukemia. *Genes Chromosomes and Cancer*, **1998**, 23, 36-43	5	11
5	Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. *Genes Chromosomes and Cancer*, **1998**, 23, 220-226	5	18
4	TAL1 expression does not occur in the majority of T-ALL blasts. *British Journal of Haematology*, **1998**, 102, 449-57	4.5	15
3	Abnormal intestinal intraepithelial lymphocytes in refractory sprue. *Gastroenterology*, **1998**, 114, 471-81	13.3	311
2	Simultaneous SIL-TAL1 RT-PCR detection of all tal(d) deletions and identification of novel tal(d) variants. *British Journal of Haematology*, **1997**, 99, 901-7	4.5	32
1	Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study. *Leukemia and Lymphoma*,1-9	1.9	